anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
MAIA Biotechnology · pitchdeck

MAIA Biotechnology | Investor Presentation Deck | 35 slides

35 pages · 4 arc beats · 2 loops

Pitchdeck Download JSON
Unlock

MAIA Biotechnology | Investor Presentation Deck | 35 slides

MAIA Biotechnology · 2023-07
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 2
— No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.
—

Deck intelligence map

4
coverage by narrative range · generated from this deck JSON
Narrative range 10 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Problem 2 slides 100% 2/2 slides 100% 2/2 slides · 10 hits
— 0/2 slides
100% 2/2 slides 50% 1/2 slides 100% 2/2 slides 100% 2/2 slides Solution 4 slides 100% 4/4 slides 100% 4/4 slides · 16 hits
— 0/4 slides
50% 2/4 slides 25% 1/4 slides 100% 4/4 slides 100% 4/4 slides · 7 hits Market Size 2 slides 100% 2/2 slides 100% 2/2 slides · 12 hits
— 0/2 slides
— 0/2 slides
— 0/2 slides
100% 2/2 slides
— 0/2 slides
Team 2 slides 100% 2/2 slides 100% 2/2 slides · 14 hits
— 0/2 slides
— 0/2 slides
— 0/2 slides
100% 2/2 slides
— 0/2 slides

Slide inventory

35
every slide · same image gating as the playbook
01
Slide 1
front_matter
Open slide detail
02
other
Open slide detail
03
other
Open slide detail
04
The slide outlines clinical trial progress (THIO-101, 102, 103), regulatory designations, and intellectual property status.summarize
Open slide detail
05
The slide uses a Gantt-style visualization to track drug development progress.plan_implementation
Open slide detailBeat · ProblemLoop · Cost Of Inaction
06
The slide uses a chromosome icon for the lead asset and a fast-forward icon for the pipeline.present_solution
Open slide detailBeat · ProblemLoop · Cost Of Inaction
07
transition
Open slide detailBeat · SolutionLoop · Cost Of Inaction
08
The slide uses a three-column layout to present demographic and health statistics related to aging and cancer.establish_context
Open slide detailBeat · SolutionLoop · Cost Of Inaction
09
present_solution
Open slide detailBeat · SolutionLoop · Cost Of Inaction
10
The slide illustrates the biological interaction between THIO (telomere targeting) and CPIs (checkpoint inhibitors) to induce tumor cell death.present_solution
Open slide detailBeat · SolutionLoop · Cost Of Inaction
11
Slide highlights a strategic partnership/validation event.show_traction
Open slide detailLoop · Why Now
12
The slide outlines a clinical trial process flow from initial NSCLC 2L+ patient entry through randomization to expansion.plan_implementation
Open slide detailLoop · Why Now
13
The slide uses a bulleted list to present clinical trial safety findings.show_traction
Open slide detail
14
The slide highlights low-grade adverse events to support a claim of a favorable safety profile.analyze_data
Open slide detail
15
The slide highlights exceptional progression-free survival in a high-need patient population.show_traction
Open slide detail
16
The slide defines DCR and provides a comparative analysis against standard of care (SOC) in third-line therapy.show_traction
Open slide detail
17
The chart uses a swimmer plot format to visualize patient status (on treatment vs follow-up) and survival duration.analyze_data
Open slide detail
18
The chart shows tumor volume over time, highlighting the superior performance of the THIO + Atezo combination compared to monotherapies and control.present_solution
Open slide detail
19
The table compares clinical trial metrics for THIO-101 targets versus existing chemotherapy SoC.compare_peers
Open slide detail
20
The slide shows a confocal microscopy image alongside a dot plot quantifying TIFs over time (0, 24, 48, 72 hours).show_traction
Open slide detail
21
The slide outlines a clinical trial design using a basket/umbrella approach to test THIO in combination with various anti-PD-1/PD-L1 therapies.plan_implementation
Open slide detail
22
The slide uses two line charts to demonstrate tumor volume reduction and the effect of rechallenge.present_solution
Open slide detail
23
The table compares clinical endpoints (Toxicity, ORR, PFS, OS) for the current standard of care (LONSURF) against the trial's goals.compare_peers
Open slide detail
24
The slide shows tumor volume reduction over time in two different cancer models (SCLC and HCC) comparing control groups against various THIO-based combination tshow_traction
Open slide detail
25
The chart shows tumor volume over time (days) with error bars, highlighting the efficacy of THIO.show_traction
Open slide detail
26
Shows two distinct experiments: initial tumor growth inhibition and subsequent rechallenge immunity.show_traction
Open slide detail
27
The slide outlines a clinical development pathway involving immune activation and combination therapies.plan_implementation
Open slide detail
28
The slide outlines both regulatory exclusivity (NCE status) and a multi-layered patent strategy.present_solution
Open slide detail
29
Includes a logo grid at the bottom representing past company affiliations.other
Open slide detailBeat · Team
30
Includes footnotes regarding option ownership and cash proceeds, plus a note on insider ownership percentage.analyze_data
Open slide detailBeat · Team
31
transition
Open slide detail
32
The chart compares the massive combined market of major CPIs ($42B) against a smaller reference point ($0.5B).size_opportunity
Open slide detailBeat · Market Size
33
The slide highlights a recent acquisition event as a benchmark for valuation.compare_peers
Open slide detailBeat · Market Size
34
The slide uses a timeline format with star icons to denote major inflection points.plan_implementation
Open slide detail
35
The slide serves as social proof and a milestone marker for the company's public listing.show_traction
Open slide detail